What triggered the FY26 guidance upgrade for Nova Eye Medical (ASX:EYE)?

Nova Eye Medical upgraded its fiscal year 2026 sales guidance following a period of record-breaking sales in the North American market. The company achieved a new monthly sales record in the USA during April 2026, which surpassed the previous record set just one month earlier in March.

How much did Nova Eye Medical (ASX:EYE) increase its sales guidance?

The company raised its FY26 sales guidance (excluding China) to a new range of US$22–23 million. This is an increase from the previous guidance of US$21–22 million. This adjustment reflects strong trading momentum with two months remaining in the financial year.

What are the key sales figures for Nova Eye Medical (ASX:EYE) as of April 2026?

As of April 30, 2026, the group’s trailing twelve-month (TTM) sales reached US$22.8 million, representing a 26% increase over the prior comparative period. When excluding the Chinese market, sales for the last twelve months reached US$21.6 million, which is a 27% increase.

Which geographic markets are driving growth for Nova Eye Medical (ASX:EYE)?

The USA is the primary growth driver, showing a 28% increase in sales over the last twelve months. Other "direct markets" also performed well, contributing to a combined 26% growth rate in those regions, while the "Rest of World" (ROW) segment grew by 39%.

Why is the USA market performance critical for the Nova Eye Medical (ASX:EYE) investment thesis?

The USA is Nova Eye Medical’s largest market, accounting for approximately US$17.76 million of the US$22.8 million in group sales. Consistent record-breaking monthly sales in this region validate the company's direct sales strategy and the adoption of its ophthalmic treatment technologies.

How does the current performance of Nova Eye Medical (ASX:EYE) compare to last year?

The company has seen significant expansion, with group sales rising from US$18.1 million in the prior comparative period to US$22.8 million. Sales specifically in direct markets grew 26%, while sales excluding China jumped from US$17.1 million to over US$21.6 million.

Nova Eye Medical upgrades FY26 sales guidance

Written by Liezl GambePublished May. 5 2026Last Updated May. 5 2026

Nova Eye Medical (ASX:EYE) announced a boost to its fiscal year 2026 outlook following a streak of record-breaking performances in the North American market.

The medical technology specialist, renowned for its advanced ophthalmic treatment devices, revealed that April 2026 marked a new monthly sales record in the USA, surpassing the previous high established only a month prior in March.

The sustained momentum has propelled the group’s trailing twelve-month sales to US$22.8 million, representing a 26% increase over the previous comparative period.

The company's performance was particularly strong across its direct markets, with the USA leading the charge with a 28% growth rate.

Excluding the Chinese market, last twelve-month sales reached US$21.6 million by April 30.

With two months of the 2026 financial year remaining and trading momentum showing no signs of slowing, management has officially upgraded its FY26 sales guidance (excluding China).

The forecast has been raised to a range of US$22–23 million, up from the previous estimate of US$21–22 million.

At the time of reporting, Nova Eye Medical’s share price was $0.13.